Xenon Pharmaceuticals Halts Enrollment in Clinical Trials for Azetukalner Due to Side Effects
Xenon Pharmaceuticals (NASDAQ: XENE) has voluntarily halted enrollment in several clinical studies involving its experimental drug azetukalner due to unexpected side effects. The decision came after a significant one-day stock surge of 50% on March 9, driven by positive trial results for the epilepsy treatment candidate. The biotech company's shares have since plummeted to a 10-month low following Friday’s announcement. Azetukalner was seen as a key asset in Xenon's pipeline with potential regulatory approval looming. The halt raises concerns about its safety profile and could delay or complicate the drug’s path toward market authorization. The move reflects broader risks inherent in biotech development, where adverse events can quickly reverse investor optimism.
Tickers: $XENE
Topics: biotech drug development stock movement